- Home
- SCPH vs NLSP Comparison
SCPH vs NLSP Comparison
Compare SCPH & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- NLSP
- Stock Information
- Founded
- SCPH 2013
- NLSP 2015
- Country
- SCPH United States
- NLSP Switzerland
- Employees
- SCPH N/A
- NLSP N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- SCPH Health Care
- NLSP Health Care
- Exchange
- SCPH Nasdaq
- NLSP Nasdaq
- Market Cap
- SCPH 274.7M
- NLSP 243.8M
- IPO Year
- SCPH 2017
- NLSP 2021
- Fundamental
- Price
- SCPH $3.35
- NLSP $3.43
- Analyst Decision
- SCPH Strong Buy
- NLSP
- Analyst Count
- SCPH 2
- NLSP 0
- Target Price
- SCPH $15.00
- NLSP N/A
- AVG Volume (30 Days)
- SCPH 503.0K
- NLSP 629.5K
- Earning Date
- SCPH 11-13-2024
- NLSP 11-29-2024
- Dividend Yield
- SCPH N/A
- NLSP N/A
- EPS Growth
- SCPH N/A
- NLSP N/A
- EPS
- SCPH N/A
- NLSP N/A
- Revenue
- SCPH $30,278,000.00
- NLSP N/A
- Revenue This Year
- SCPH $195.62
- NLSP N/A
- Revenue Next Year
- SCPH $145.07
- NLSP N/A
- P/E Ratio
- SCPH N/A
- NLSP N/A
- Revenue Growth
- SCPH 303.87
- NLSP N/A
- 52 Week Low
- SCPH $3.08
- NLSP $3.00
- 52 Week High
- SCPH $6.71
- NLSP $29.08
- Technical
- Relative Strength Index (RSI)
- SCPH 33.76
- NLSP 39.10
- Support Level
- SCPH $3.25
- NLSP $3.01
- Resistance Level
- SCPH $3.60
- NLSP $3.55
- Average True Range (ATR)
- SCPH 0.24
- NLSP 0.38
- MACD
- SCPH -0.05
- NLSP 0.01
- Stochastic Oscillator
- SCPH 19.30
- NLSP 32.09
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.